FDA approves tirzepatide for CV risk reduction in type 2 diabetes after SURPASS-CVOT
Louis shares that the FDA approved tirzepatide to lower heart attack and stroke risk in type 2 diabetes, based on SURPASS-CVOT. In 13,299 adults with established heart disease, tirzepatide was noninferior to dulaglutide for MACE (12.2% vs 13.1%, HR 0.92), without formally reaching superiority.





